基于增强CMR的MVO与IMH范围风险评分
本研究为回顾性多中心研究,纳入568例STEMI患者,利用LGE评估微血管阻塞(MVO),利用T2* mapping及T2加权CMR评估心肌内出血(IMH)。结果显示MVO>1.06% LV且IMH>0.47% LV是MACE的最强预测因子(HR 9.646,95%CI 6.327-14.705,p<0.001)。联合GRACE评分、LVEF及定量MVO和IMH的Score 3预测MACE的AUC达0.853,优于GRACE评分(AUC 0.748)、Score 1(AUC 0.825)和Score 2(AUC 0.802)。
要点
- MVO>1.06% LV且IMH>0.47% LV时,MACE风险显著升高(HR 9.646)。
- 报告应同时描述MVO和IMH的定量范围,而非仅定性判断。
- 联合GRACE评分、LVEF≤45%、MVO和IMH范围可提高STEMI预后分层效能(AUC 0.853)。
核心结论
- 联合MVO>1.06% LV和IMH>0.47% LV是STEMI患者MACE的最强预测因子(HR 9.646,95%CI 6.327-14.705,p<0.001)。
- 整合GRACE评分、LVEF≤45%、定量MVO和IMH范围的Score 3预测MACE的AUC为0.853,优于GRACE评分、Score 1和Score 2。
研究设计与样本
- 回顾性多中心研究,纳入568例STEMI患者。
- MVO采用晚期钆增强(LGE)评估,IMH采用T2* mapping和T2加权CMR评估。
- 中位随访3.1年(IQR 1.7-5.0年),108例(19%)发生MACE。
关键影像表现/征象
- MVO在LGE上显示为梗死核心内的低信号或无强化区。
- IMH在T2加权及T2* mapping上表现为梗死区内的低信号区。
- MACE事件率随MVO和IMH范围分组逐级升高,从8.8%增至58.3%。
诊断标准与关键数值
- MVO阈值:>1.06% LV;IMH阈值:>0.47% LV,采用约登指数确定。
- MVO>1.06% LV且IMH>0.47% LV联合预测MACE的HR为9.646(95%CI 6.327-14.705,p<0.001)。
- Score 3包含LVEF≤45%、MVO>1.06% LV、IMH>0.47% LV及GRACE评分,AUC为0.853。
- 对照评分AUC:GRACE评分0.748,Score 1为0.825,Score 2为0.802。
临床应用与阅片要点
- STEMI再灌注后CMR报告应量化MVO占左室百分比及IMH占左室百分比。
- 当MVO>1.06% LV且IMH>0.47% LV同时存在时,应提示MACE高风险。
- 建议将定量MVO和IMH范围与LVEF及GRACE评分结合用于STEMI预后评估。
- T2* mapping和T2加权成像应作为常规序列用于检测IMH,LGE用于检测MVO。
局限性
- 本研究为回顾性多中心设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study aims to compare the prognostic value of the extent of microvascular obstruction (MVO) combined with intramyocardial hemorrhage (IMH) for major adverse cardiovascular events (MACE) in patients with STEMI.
MATERIALS AND METHODS: We analyzed 568 STEMI patients in this retrospective multicenter study. Microvascular injury was visualized using late gadolinium enhancement for MVO, and T2* mapping and T2-weighted cardiovascular magnetic resonance imaging for IMH. The Youden index was used as the cutoff value to divide the study population into four groups. The Eitel CMR risk score, Glasgow CMR risk score, and GRACE (Global Registry of Acute Coronary Events) score were used as references to form Scores 1 and 2. Score 3 included LVEF ≤ 45%, MVO > 1.06% LV, IMH > 0.47% LV, and the GRACE score.
RESULTS: During a median follow-up of 3.1 years (IQR: 1.7-5.0 years), 108 patients (19%) experienced MACE. Event rates increased stepwise across groups (8.8% to 58.3%). The combination of MVO > 1.06% LV and IMH > 0.47% LV emerged as the strongest predictor of MACE (HR: 9.646, 95% CI: 6.327-14.705 [p < 0.001]). Score 3 (integrating GRACE score, LVEF, and quantitative MVO and IMH) demonstrated improved predictive performance for MACE compared to the GRACE score (AUC: 0.748), Score 1 (AUC: 0.825), and Score 2 (AUC: 0.802), achieving an AUC of 0.853.
CONCLUSION: Our approach integrates quantitative information on MVO and IMH into a risk score that shows better prognostic value than established risk scores.
KEY POINTS: Question Current prognostic tools for ST-elevation myocardial infarction patients lack quantitative combined assessment of microvascular obstruction and intramyocardial hemorrhage, limiting precise risk stratification after reperfusion. Findings A novel cardiac magnetic resonance score integrating quantitative microvascular obstruction and intramyocardial hemorrhage extent achieved 0.853 area under the curve for major adverse cardiovascular events. Critical Relevance Statement This study develops a quantitative cardiac magnetic resonance risk score by integrating microvascular obstruction and intramyocardial hemorrhage, offering improved prognostic value for major adverse cardiovascular events in ST-elevation myocardial infarction patients over established clinical scores.
引用
- Gu, Yin, Yu, et al. A contrast-enhanced CMR-based risk score integrating microvascular obstruction and intramyocardial hemorrhage extent for prognostic evaluation. Insights Imaging. 2026. PMID: 42658441. doi:10.1186/s13244-026-02386-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。